Rep. Lisa C. McClain Sells Off Shares of Kenvue Inc. (NYSE:KVUE)

Representative Lisa C. McClain (R-Michigan) recently sold shares of Kenvue Inc. (NYSE:KVUE). In a filing disclosed on November 21st, the Representative disclosed that they had sold between $1,001 and $15,000 in Kenvue stock on October 30th. The trade occurred in the Representative’s “CHARLES SCHWAB BROKERAGE ACCOUNT 924” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

Kenvue Trading Up 0.4%

Shares of NYSE:KVUE traded up $0.08 during midday trading on Friday, hitting $17.30. 9,189,777 shares of the stock traded hands, compared to its average volume of 24,055,268. The company has a quick ratio of 0.69, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. The business’s 50 day moving average is $16.08 and its two-hundred day moving average is $19.64. The stock has a market capitalization of $33.13 billion, a PE ratio of 23.06 and a beta of 0.71. Kenvue Inc. has a one year low of $14.02 and a one year high of $25.17.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. The company had revenue of $3.76 billion during the quarter, compared to analysts’ expectations of $3.83 billion. During the same period last year, the company posted $0.28 EPS. Kenvue’s revenue was down 3.5% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, research analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, November 26th. Investors of record on Wednesday, November 12th were given a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a yield of 4.8%. The ex-dividend date was Wednesday, November 12th. Kenvue’s dividend payout ratio (DPR) is presently 110.67%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on KVUE. Edward Jones downgraded shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 3rd. Royal Bank Of Canada decreased their price objective on Kenvue from $24.00 to $22.00 and set a “sector perform” rating on the stock in a research note on Friday, August 8th. Rothschild Redb raised shares of Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, September 26th. Bank of America dropped their price target on shares of Kenvue from $25.00 to $21.00 and set a “buy” rating for the company in a research report on Wednesday, October 8th. Finally, Jefferies Financial Group decreased their price objective on shares of Kenvue from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $20.23.

Hedge Funds Weigh In On Kenvue

Several institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in Kenvue by 1.8% in the second quarter. Vanguard Group Inc. now owns 233,246,267 shares of the company’s stock worth $4,881,844,000 after purchasing an additional 4,101,880 shares during the last quarter. Geode Capital Management LLC raised its position in Kenvue by 1.2% during the second quarter. Geode Capital Management LLC now owns 49,001,887 shares of the company’s stock valued at $1,021,267,000 after purchasing an additional 604,953 shares during the period. American Century Companies Inc. lifted its stake in shares of Kenvue by 22.4% in the 3rd quarter. American Century Companies Inc. now owns 37,046,660 shares of the company’s stock valued at $601,267,000 after purchasing an additional 6,781,640 shares during the last quarter. Independent Franchise Partners LLP boosted its holdings in shares of Kenvue by 233.4% in the 2nd quarter. Independent Franchise Partners LLP now owns 31,265,574 shares of the company’s stock worth $654,388,000 after purchasing an additional 21,886,537 shares during the period. Finally, Norges Bank bought a new position in shares of Kenvue during the 2nd quarter valued at approximately $537,418,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.